10-Q: AngioDynamics Q1 FY26: Sales Up 12.2%, Net Loss Narrows

AngioDynamics reports a 12.2% increase in net sales to $75.7 million and a reduced net loss of $10.9 million for the first quarter of fiscal year 2026, driven by strong Med Tech performance.

Summary

• Net sales increased by 12.2% to $75.7 million for the three months ended August 31, 2025, compared to $67.5 million in the prior year period.
• Net loss decreased by $1.9 million to $10.9 million, or $0.26 per diluted share, from $12.8 million, or $0.31 per diluted share, in the prior year.
• Med Tech segment net sales grew by 26.1% to $35.3 million, primarily driven by Auryon, thrombus management platform (AngioVac and AlphaVac), and NanoKnife disposable sales.
• Med Device segment net sales increased by 2.3% to $40.5 million, with growth in Venous, Core, and Oncology products, partially offset by declines in Ports and Microwave.
• Total gross margin improved by 90 basis points to 55.3%.
• Cash and cash equivalents decreased by $17.1 million to $38.8 million as of August 31, 2025, from $55.9 million at May 31, 2025.
• Net cash used in operating activities decreased to $15.9 million from $18.3 million in the prior year period.
• Restructuring activities related to optimizing manufacturing footprint are expected to be completed in the third quarter of fiscal year 2026, with total estimated costs revised to $33.4 million to $38.4 million.

Sentiment

Score: 6

Explanation: The company demonstrated strong revenue growth and a reduced net loss, particularly driven by its Med Tech segment. Gross margin also improved. However, cash reserves decreased, and operating expenses increased in sales & marketing and general & administrative. Significant legal proceedings and a full valuation allowance on deferred tax assets remain concerns. The new revolving credit facility provides liquidity, but future acquisitions may necessitate further external financing.

Positives

• Net sales increased by 12.2% year-over-year to $75.7 million.
• Net loss significantly narrowed by $1.9 million, from $12.8 million to $10.9 million.
• Loss per share improved by $0.05, from $0.31 to $0.26.
• Med Tech segment sales showed robust growth of 26.1%, driven by Auryon (+$2.7 million), thrombus management platform (+$3.2 million), and NanoKnife (+$1.4 million).
• Overall gross margin improved by 90 basis points to 55.3%.
• Med Device gross margin increased by 120 basis points to 49.3%.
• Net cash used in operating activities decreased by $2.3 million, indicating improved operational cash efficiency.
• Shift from cash used in financing activities ($-0.5 million) to cash provided (+$0.1 million) year-over-year.
• Operating loss improved by $2.4 million, from $(13.1) million to $(10.7) million.
• Acquisition, restructuring, and other items, net, decreased by $1.6 million, reflecting lower legal and plant closure expenses.

Negatives

• Cash and cash equivalents decreased by $17.1 million during the quarter, from $55.9 million to $38.8 million.
• Med Tech gross margin decreased by 110 basis points to 62.2%.
• Tariffs negatively impacted total gross margin by $1.7 million.
• Production volume negatively impacted total gross margin by $0.3 million.
• Incremental depreciation on placement units negatively impacted total gross margin by $0.6 million.
• Selling and marketing expenses increased by $2.5 million, primarily due to compensation and benefits.
• General and administrative expenses increased by $1.6 million, mainly due to compensation and benefits.
• The company maintains a full valuation allowance on its U.S. deferred tax assets, indicating uncertainty about realizing future tax benefits.
• Approximately 219 product liability claims are pending against the company related to its port products.

Risks

• Ability to develop existing and new products.
• Technological advances and patents attained by competitors.
• Infringement of company's technology or assertions that company's technology infringes third-party technology.
• Ability to effectively compete against competitors with substantially greater resources.
• Future actions by the FDA or other regulatory agencies.
• Domestic and foreign health care reforms and government regulations.
• Results of pending or future clinical trials.
• Overall economic conditions, including inflation, tariffs, labor shortages, and supply chain challenges (cost and availability of raw materials).
• Results of ongoing litigation, including the 219 product liability claims involving port products and the contingent payment related to the BD patent appeal.
• Challenges with respect to third-party distributors or joint venture partners or collaborators.
• Effects of product recalls and product liability claims.
• Changes in key personnel.
• Ability to execute on strategic initiatives.
• Effects of economic, credit, and capital market conditions.
• General market conditions and market acceptance of products.
• Foreign currency exchange rate fluctuations, particularly for sales denominated in Euro, British Pound, and Canadian Dollar.
• Effects on pricing from group purchasing organizations and competition.
• Ability to obtain regulatory clearances or approval of its products.
• Ability to integrate acquired businesses.
• The company has not yet attained a sustained level of profitability, and objectively verifiable negative evidence outweighs positive evidence, leading to a full valuation allowance on deferred tax assets.

Future Outlook

The company expects its businesses to grow in both sales and profitability by expanding geographically, penetrating new markets, introducing new products, and increasing its international presence. Management believes current cash on hand, cash generated from operations, and the new $25.0 million revolving credit facility will provide sufficient liquidity for at least the next 12 months. However, future acquisitions of other businesses or technologies for cash may require external financing. Restructuring activities are anticipated to be completed in the third quarter of fiscal year 2026.

Management Comments

• Our execution strategy is built on innovative R&D, clinical and regulatory pathway expansion and customer centric sales performance.
• We expect our businesses to grow in both sales and profitability by expanding geographically, penetrating new markets, introducing new products and increasing our presence internationally.
• The current macroeconomic environment continues to impact our business and may continue to pose future risks.
• We believe that our current cash balance, together with cash generated from operations and the Revolving Facility will provide sufficient liquidity to meet our anticipated needs for capital for at least the next 12 months.
• If we seek to make acquisitions of other businesses or technologies in the future for cash, we may require external financing.

Industry Context

AngioDynamics operates in the dynamic medical technology sector, focusing on cardiovascular disease and cancer. The industry is characterized by evolving market dynamics such as value-based purchasing, healthcare provider consolidation, increased consumer involvement in health decisions, and an aging population. The company's growth is also influenced by competitor mergers, changes in the regulatory environment for medical devices, and global economic fluctuations. The macroeconomic environment, including inflation, tariffs, labor shortages, and supply chain challenges, continues to impact the business, reflecting broader industry pressures. The company's strategy of investing in R&D and expanding product offerings aligns with the industry's continuous need for innovation and clinical advancement.

Comparison to Industry Standards

• The filing does not provide specific comparable company data or industry benchmarks to assess AngioDynamics' performance against global standards.
• The company's focus on minimally invasive, image-guided procedures and its segments (Med Tech and Med Device) align with key growth areas in the broader medical device industry.
• The 26.1% growth in the Med Tech segment, driven by Auryon, thrombus management, and NanoKnife, suggests strong performance in innovative, high-growth areas, which is generally favorable compared to more mature medical device markets.
• The overall gross margin improvement to 55.3% is a positive indicator, but without specific industry averages or competitor margins, a detailed assessment against global benchmarks is not possible from this filing alone.
• The ongoing legal proceedings and product liability claims are a common, albeit undesirable, aspect of the medical device industry, which is heavily regulated and prone to such challenges.

Corporate Governance

Legal Proceedings

• Settlement agreement with Becton, Dickinson and Company (BD) on March 31, 2024, resolving multiple patent infringement litigations.
• Under the BD settlement, AngioDynamics made a one-time lump sum payment of $7.0 million (partially paid, remainder by March 31, 2025) and will make six minimum annual payments of $2.5 million starting in fiscal year 2025, with potential additional payments.
• A contingent payment of $3.0 million is due to BD if the Federal Circuit reverses or vacates District Court findings of invalidity in a pending appeal (oral argument October 8, 2025).
• Approximately 219 product liability claims (Port Product Claims) are pending against the company, consolidated for pretrial proceedings in the United States District Court for the Southern District of California, seeking damages for personal injury allegedly resulting from product use.

Stakeholder Impact

• Shareholders: Potential for increased value from revenue growth and reduced losses, but diluted by ongoing net losses and cash burn. Share repurchase program offers potential for capital return. Legal proceedings and product liability claims pose financial risks.
• Employees: Restructuring plan involves optimizing manufacturing footprint, which could impact employment in certain locations, though a presence is maintained in Queensbury, NY. Share-based compensation plans are in place.
• Customers: Continued product innovation and expansion of treatment options in cardiovascular disease and cancer. Backlog of $0.4 million primarily impacting Core products could suggest minor supply constraints.
• Suppliers: Macroeconomic environment, including supply chain challenges and raw material costs, continues to impact the business.
• Creditors: New $25.0 million secured revolving credit facility provides access to capital, with no amounts outstanding as of August 31, 2025.

Next Steps

• Completion of restructuring activities associated with the modified plan in the third quarter of fiscal year 2026.
• Oral argument in the appeal before the Federal Circuit for the March 10, 2015 patent infringement case on October 8, 2025.
• Payment of the remainder of the $7.0 million lump sum to BD by March 31, 2025.
• Ongoing assessment of the level of the valuation allowance required for deferred tax assets.
• Potential future external financing if the company seeks to make acquisitions of other businesses or technologies for cash.
• Adoption of ASU 2023-09 (Income Tax Disclosures) for the fiscal year 2026 Annual Report on Form 10-K.
• Adoption of ASU 2025-05 (Financial Instruments-Credit Losses) for the fiscal year 2027.
• Adoption of ASU 2024-03 (Expense Disaggregation Disclosures) for the fiscal year 2028.

Key Dates

Recommendation

While AngioDynamics demonstrated strong revenue growth, particularly in its Med Tech segment, and a significant reduction in net loss, the company continues to operate at a net loss and experienced a notable decrease in cash reserves during the quarter. The improved gross margin is positive, but increased operating expenses in sales & marketing and general & administrative, coupled with ongoing legal proceedings and product liability claims, present continued financial and operational uncertainties. The full valuation allowance on deferred tax assets also signals a lack of sustained profitability. The new revolving credit facility provides liquidity, but the overall financial position suggests a "hold" recommendation as the company navigates its restructuring, manages litigation, and works towards sustained profitability. Investors should monitor the completion of restructuring, resolution of legal matters, and continued growth in key product lines.

Keywords

Medical Technology, Med Tech, Med Device, AngioDynamics, SEC Filing, 10-Q, Financial Results, Quarterly Report, Auryon, NanoKnife, Thrombus Management, Vascular Access, Oncology, Peripheral Vascular Disease, Medical Devices, Financial Performance, Revenue Growth, Net Loss, Gross Margin, Cash Flow, Restructuring, Litigation, Patent Infringement, Product Liability, Share Repurchase, Credit Facility, Healthcare Industry, Financial Reporting